CorVel (NASDAQ:CRVL) Hits New 1-Year Low – What’s Next?

CorVel Corp. (NASDAQ:CRVL)’s share price reached a new 52-week low on Monday . The company traded as low as $46.71 and last traded at $46.82, with a volume of 44287 shares traded. The stock had previously closed at $48.67.

Analysts Set New Price Targets

A number of equities analysts have recently commented on CRVL shares. Weiss Ratings reiterated a “hold (c)” rating on shares of CorVel in a research note on Friday, January 9th. Wall Street Zen lowered CorVel from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. One research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Hold”.

CorVel Stock Down 5.5%

The stock has a market capitalization of $2.35 billion, a price-to-earnings ratio of 22.55 and a beta of 1.06. The stock’s 50-day simple moving average is $67.78 and its 200 day simple moving average is $76.02.

CorVel (NASDAQ:CRVL) last released its quarterly earnings results on Tuesday, February 3rd. The business services provider reported $0.47 EPS for the quarter. The business had revenue of $235.63 million for the quarter. CorVel had a return on equity of 30.15% and a net margin of 11.23%.

Insider Buying and Selling

In other news, EVP Mark E. Bertels sold 1,200 shares of the business’s stock in a transaction on Wednesday, November 19th. The stock was sold at an average price of $72.35, for a total transaction of $86,820.00. Following the completion of the sale, the executive vice president owned 2,594 shares in the company, valued at $187,675.90. The trade was a 31.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director R Judd Jessup sold 7,076 shares of the company’s stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $76.94, for a total value of $544,427.44. Following the transaction, the director directly owned 115,045 shares in the company, valued at $8,851,562.30. This trade represents a 5.79% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 44.56% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC grew its position in shares of CorVel by 3.2% during the 4th quarter. Geode Capital Management LLC now owns 927,845 shares of the business services provider’s stock worth $62,796,000 after buying an additional 28,666 shares during the period. Themes Management Co LLC bought a new position in CorVel in the fourth quarter valued at approximately $341,000. Covestor Ltd grew its holdings in CorVel by 25.7% during the 4th quarter. Covestor Ltd now owns 1,949 shares of the business services provider’s stock worth $132,000 after acquiring an additional 399 shares during the period. PNC Financial Services Group Inc. raised its position in shares of CorVel by 14.4% during the 4th quarter. PNC Financial Services Group Inc. now owns 2,008 shares of the business services provider’s stock valued at $136,000 after acquiring an additional 252 shares during the last quarter. Finally, Handelsbanken Fonder AB lifted its stake in shares of CorVel by 37.5% in the 4th quarter. Handelsbanken Fonder AB now owns 12,100 shares of the business services provider’s stock valued at $819,000 after purchasing an additional 3,300 shares during the period. 51.36% of the stock is currently owned by institutional investors and hedge funds.

CorVel Company Profile

CorVel Corporation (NASDAQ: CRVL) is a technology-driven provider of workers’ compensation, liability, and specialty risk management solutions. The company develops and deploys software and data analytics tools to streamline claims administration, medical cost containment, prescription drug management, and provider network access. CorVel’s integrated platform connects employers, insurers, healthcare providers, and injured workers, aiming to improve outcomes and control costs through process automation and real-time decision support.

The company’s product suite includes claims lifecycle management, bill review and negotiation, virtual care and telehealth services, pharmacy benefit management, and independent medical examinations (IMEs).